| Market Cap | 7.66M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -10.47M | Forward P/E | -2.43 | EPS next Y | - | 50D Avg Chg | -21.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -65.00% |
| Dividend | N/A | Price/Book | 1.49 | EPS next 5Y | - | 52W High Chg | -87.00% |
| Recommedations | 2.00 | Quick Ratio | 3.58 | Shares Outstanding | 2.52M | 52W Low Chg | 15.00% |
| Insider Own | 21.90% | ROA | -46.55% | Shares Float | 1.23M | Beta | 1.91 |
| Inst Own | 40.09% | ROE | -150.25% | Shares Shorted/Prior | 13.07K/13.51K | Price | 3.18 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 31,312 | Target Price | - |
| Oper. Margin | - | Earnings Date | Nov 11 | Volume | 22,805 | Change | 2.25% |
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hecht Peter M | Chief Executive Offi.. Chief Executive Officer | May 06 | Buy | 2.41 | 698,001 | 1,682,182 | 922,528 | 05/06/21 |